Clinical trials: Retinal Vascularisation
Choroidal Neovascularization, Wet Macular Degeneration
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.
- Trial name
- DECO (NCT03452527)
- Testing
- ICON-1, aflibercept
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Iconic Therapeutics, Inc.
Age Related Macular Degeneration, Choroidal Neovascularization
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A.
- Trial name
- NCT00331864
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 531 people
- Sponsor
- Novartis
Diabetic Retinopathy
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18…
- Trial name
- POC1 (NCT00511875)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Gardner
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Choroidal Neovascularization, Age-related Macular Degeneration
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared…
- Trial name
- EMERGE (NCT02358889)
- Testing
- hI-con1, ranibizumab
- Where
- 48 sites in United States
- Volunteers
- 88 people
- Sponsor
- Iconic Therapeutics, Inc.
Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)
To evaluate and compare two individualised ranibizumab treatment regimens, differentiated by the definition of disease activity, which determines the treatment interval until the next injection.
- Trial name
- FLUID (NCT01972789)
- Testing
- Ranibizumab
- Where
- 16 sites in Australia
- Volunteers
- 349 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823287
- Testing
- Faricimab, Aflibercept
- Where
- 161 sites in United States, Canada and 13 more
- Volunteers
- 671 people
- Sponsor
- Hoffmann-La Roche
Macular Degeneration
Ranibizumab and Reduced Fluence PDT for AMD
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration.
- Trial name
- RAP (NCT00527475)
- Testing
- ranibizumab, verteporfin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Texas Retina Associates
Age Related Macular Degeneration
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
- Trial name
- EXCITE (NCT00275821)
- Testing
- Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly
- Where
- Switzerland
- Volunteers
- 353 people
- Sponsor
- Novartis
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- NCT03823300
- Testing
- Faricimab, Aflibercept
- Where
- 137 sites in United States, Argentina and 19 more
- Volunteers
- 658 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision
Macular Degeneration, Wet Macular Degeneration
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
- Trial name
- EAGLE (NCT02689518)
- Testing
- Intravitreal aflibercept injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Macular Degeneration
Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)
The objective of this study is to determine if combination therapy (reduced-fluence Visudyne followed by Lucentis [within 2 hours] or either of two regimens of reduced-fluence Visudyne followed by Lucentis-Dexamethasone triple…
- Trial name
- RADICAL (NCT00492284)
- Testing
- verteporfin, ranibizumab, dexamethasone
- Where
- 26 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- QLT Inc.
Age Related Macular Degeneration (AMD), Macular Degeneration
An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD
The purpose of this study is to determine the benefits of treating subjects with neovascular age-related macular degeneration (AMD) at an earlier stage of choroidal neovascularization (CNV) as compared to those with established…
- Conditions
- Age Related Macular Degeneration (AMD), Macular Degeneration, Choroidal Neovascularization (CNV)
- Trial name
- PERSPECTIVES (NCT00327470)
- Testing
- Pegaptanib Sodium 0.3 mg
- Where
- 58 sites in Austria, Belgium and 13 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization…
- Trial name
- NCT01122511
- Testing
- 700 ug dexamethasone, ranibizumab
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Allergan
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Macular Degeneration
To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD
This is a 28 day study to evaluate the pharmacodynamic effect of pazopanib eye drops on the central retinal thickness of AMD patients
- Trial name
- NCT00612456
- Testing
- Pazopanib
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Polypoidal Choroidal Vasculopathy
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with…
- Trial name
- PCV (NCT00674323)
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 5 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 61 people
- Sponsor
- Novartis
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects…
- Trial name
- NCT01940887
- Testing
- E10030, bevacizumab or aflibercept
- Where
- 207 sites in United States, Argentina and 20 more
- Volunteers
- 645 people
- Sponsor
- Ophthotech Corporation